Company Overview and News
Overseas Filipinos have become purveyors of a new ultra-modern lifestyle that is rapidly being introduced to every corner of the Philippines, says one observer.
FVSMF AYAAY FLI ALI AYAAF
CLARK, PAMPANGA — Filinvest Land, Inc. (FLI) is set to finish its second office tower within the group’s 201-hectare tourism and leisure estate in Pampanga this year, as it seeks to cater to the business process outsourcing (BPO) firms flocking to the province.
Clark, Pampanga—Filinvest Land, Inc. (FLI) is set to finish its second office tower within its 201-hectare tourism and leisure estate in Pampanga this year, as it seeks to cater to the influx of business process outsourcing (BPO) firms in the province.
The Gotianun family-led Filinvest Development Corporation (FDC) reported first half net income of Php7.2B, a 45% increase vs. the same period in 2018. Majority of revenues, or 44%, were contributed by the property business – which includes both the real estate and hotel groups. Banking (38%), power (11%) and sugar (6%) contributed the balance.
FILIY FVSMF FDC FLI
KOREAN-LED Widus International Leisure, Inc., the operator of the Marriot hotel chain in Clark, Pampanga, is looking at expanding its hotel projects in the city to total to $1 billion in the next few years.
FILIY FVSMF MWP FDC GMRINFRA GMQRY FLI MWIDE 532754
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET